Avidity Biosciences
RNAM
RNAM was delisted on the 26th of February, 2026.
144 hedge funds and large institutions have $701M invested in Avidity Biosciences in 2023 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 53 increasing their positions, 47 reducing their positions, and 23 closing their positions.
119% more call options, than puts
Call options by funds: $756K | Put options by funds: $345K
34% more capital invested
Capital invested by funds: $522M → $701M (+$179M)
13% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 47
1% more funds holding
Funds holding: 142 → 144 (+2)
9% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 23
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
5.84% less ownership
Funds ownership: 110.3% → 104.46% (-5.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$12.2M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.18M |
| 3 |
BlackRock
New York
|
+$4.75M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.2M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$2.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$26.5M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$11.2M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.37M |
| 4 |
State Street
Boston,
Massachusetts
|
-$4.83M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.75M |
RNAM Hedge Fund Activity: Q4 2023 in Review
144 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Avidity Biosciences (RNAM) for Q4 2023, worth a combined $701M — up 34% from $522M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new RNAM positions and 23 closed out — a net gain of 2 holders — while 53 added to existing stakes and 47 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $12.2M. The largest seller was RA Capital Management, cutting an estimated $26.5M.
- 144 institutional investors held Avidity Biosciences (RNAM) as of Q4 2023, up from 142 in Q3 2023.
- Funds reported $701M of Avidity Biosciences stock for Q4 2023, up 34% quarter-over-quarter.
- 25 funds opened new Avidity Biosciences positions in Q4 2023 and 23 closed out, a net change of +2 holders.
- The largest Avidity Biosciences buyer in Q4 2023 was Morgan Stanley, an estimated $12.2M added.
- The largest Avidity Biosciences seller in Q4 2023 was RA Capital Management, an estimated $26.5M sold.
Based on aggregated 13F filings for Q4 2023.